文献速递消化与肝胆胰病理血液淋巴病理

抗CD40L治疗可预防小鼠胃MALT淋巴瘤前驱病变形成

Anti-CD40L therapy prevents the formation of precursor lesions to gastric B-cell MALT lymphoma in a mouse model.
PubMed 文献 · J Pathol · 2023-02-17

该研究建立了一种新的小鼠胃MALT淋巴瘤模型:髓系特异性缺失Nlrc5的小鼠在幽门螺杆菌感染后仅3个月即出现MALT淋巴瘤前驱B细胞病变,而现有模型需9-24个月。这些病变具有人类疾病的组织病理学特征,并伴有表达PD-1/PD-L1的免疫抑制微环境。给予抗CD40L抗体(与感染同时或感染建立后)可预防胃B细胞病变,并减少胃DC、CD8+和Foxp3+ T细胞及B细胞淋巴瘤基因表达。

要点

  • Nlrc5髓系敲除小鼠在幽门螺杆菌感染后3个月出现胃MALT淋巴瘤前驱病变。
  • 抗CD40L抗体可预防小鼠胃B细胞病变形成。
  • 病变微环境存在PD-1/PD-L1免疫抑制及DC、CD8+、Foxp3+ T细胞浸润。

核心结论

  • 抗CD40L抗体可预防小鼠胃MALT淋巴瘤前驱B细胞病变的形成。
  • CD40L被验证为治疗人胃B细胞MALT淋巴瘤的潜在靶点。

研究设计与样本

  • 研究采用髓系特异性Nlrc5敲除小鼠建立幽门螺杆菌诱导的胃MALT淋巴瘤前驱病变模型。
  • 小鼠在感染后3个月出现前驱B细胞病变,而现有模型需9-24个月。
  • 比较抗CD40L抗体与对照抗体在感染同时或感染建立后给药对胃B细胞病变的影响。

主要发现

  • Nlrc5敲除小鼠胃B细胞病变具有人类疾病组织病理学特征,包括淋巴上皮样病变和中心细胞样细胞。
  • 病变浸润树突状细胞、巨噬细胞及CD4+、CD8+和Foxp3+ T细胞。
  • 小鼠和人胃组织均含表达PD-1及其配体PD-L1的免疫细胞,提示免疫抑制微环境。
  • 抗CD40L抗体给药(与感染同时或感染建立后)预防胃B细胞病变,优于对照抗体。
  • 抗CD40L抗体组胃DC、CD8+和Foxp3+ T细胞数量显著减少,胃B细胞淋巴瘤基因表达下降。

临床怎么用

  • CD40L可作为胃MALT淋巴瘤治疗的潜在靶点,但需进一步临床验证。
  • Nlrc5敲除小鼠模型可加速胃MALT淋巴瘤前驱病变研究。

局限性

  • 研究仅基于小鼠模型,尚未在人体中验证CD40L靶向治疗的有效性与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mucosa-associated lymphoid tissue (MALT) lymphoma is a B-cell tumour that develops over many decades in the stomachs of individuals with chronic Helicobacter pylori infection. We developed a new mouse model of human gastric MALT lymphoma in which mice with a myeloid-specific deletion of the innate immune molecule, Nlrc5, develop precursor B-cell lesions to MALT lymphoma at only 3 months post-Helicobacter infection versus 9-24 months in existing models. The gastric B-cell lesions in the Nlrc5 knockout mice had the histopathological features of the human disease, notably lymphoepithelial-like lesions, centrocyte-like cells, and were infiltrated by dendritic cells (DCs), macrophages, and T-cells (CD4+ , CD8+ and Foxp3+ ). Mouse and human gastric tissues contained immune cells expressing immune checkpoint receptor programmed death 1 (PD-1) and its ligand PD-L1, indicating an immunosuppressive tissue microenvironment. We next determined whether CD40L, overexpressed in a range of B-cell malignancies, may be a potential drug target for the treatment of gastric MALT lymphoma. Importantly, we showed that the administration of anti-CD40L antibody either coincident with or after establishment of Helicobacter infection prevented gastric B-cell lesions in mice, when compared with the control antibody treatment. Mice administered the CD40L antibody also had significantly reduced numbers of gastric DCs, CD8+ and Foxp3+ T-cells, as well as decreased gastric expression of B-cell lymphoma genes. These findings validate the potential of CD40L as a therapeutic target in the treatment of human gastric B-cell MALT lymphoma. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

来源:J Pathol,查看原文。版权归原作者所有。

引用

  1. Ying L, Liu P, Ding Z, et al. Anti-CD40L therapy prevents the formation of precursor lesions to gastric B-cell MALT lymphoma in a mouse model. J Pathol. 2023. PMID: 36640261. doi:10.1002/path.6053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。